Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.78 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL411527 | 0.98 | TBXAS1 (0.76) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL11373689 | 0.91 | TBXAS1 (0.67) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL6949512 | 0.91 | TBXAS1 (0.89) | TBXAS1EGLN3CYP19A1 | |
| Hydrochloric Acid SCHEMBL11259498 | 0.89 | TBXAS1 (0.86) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL11375367 | 0.89 | TBXAS1 (0.64) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL11153260 | 0.87 | TBXAS1 (0.62) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL6950296 | 0.84 | TBXAS1 (0.58) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL11257445 | 0.84 | TBXAS1 (0.58) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL6948774 | 0.84 | POLB (0.60) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL1509735 | 0.83 | CYP19A1 (0.71) | TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| EP-2099762-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100069366-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (NJ) | 2010-03-18 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-5665756-A | Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders | HOECHST MARION ROUSSEL, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5648367-A | ANTIDEPRESANTS, OBSESSIVE-COMPULSIVE DISORDER | HOECHST MARION ROUSSEL, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0709378-A2 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-05-01 | — | — | EP | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4518607-A | FUNGICIDES, BACXTERICIDES AND ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
| US-4359475-A | SPERMICIDES, MICROBIOCIDES OR ANTICONVULSANTS | SYNTEX (U.S.A.) INC. (US) | 1982-11-16 | — | — | US | disclosed |
| US-4285961-A | MICROBIOCIDES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-08-25 | — | — | US | disclosed |
| US-4078071-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4045568-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TBXAS1 469/4885EGLN3 346/4885CYP19A1 884/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1071/4885EGLN3 241/4885CYP19A1 641/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1071/4885EGLN3 241/4885CYP19A1 641/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1257/4885EGLN3 348/4885CYP19A1 614/4885 |
| US-20100069366-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | TBXAS1 677/4885EGLN3 1987/4885CYP19A1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.